| Literature DB >> 32098428 |
Peter Takac1,2, Martin Kello1, Maria Vilkova3, Janka Vaskova4, Radka Michalkova1, Gabriela Mojzisova5, Jan Mojzis1.
Abstract
Chalcones are naturally occurring phytochemicals with diverse biological activities including antioxidant, antiproliferative, and anticancer effects. Some studies indicate that the antiproliferative effect of chalcones may be associated with their pro-oxidant effect. In the present study, we evaluated contribution of oxidative stress in the antiproliferative effect of acridine chalcone 1C ((2 E)-3-(acridin-9-yl)-1-(2,6-dimethoxyphenyl)prop-2-en-1-one) in human colorectal HCT116 cells. We demonstrated that chalcone 1C induced oxidative stress via increased reactive oxygen/nitrogen species (ROS/RNS) and superoxide production with a simultaneous weak adaptive activation of the cellular antioxidant defence mechanism. Furthermore, we also showed chalcone-induced mitochondrial dysfunction, DNA damage, and apoptosis induction. Moreover, activation of mitogen activated phosphokinase (MAPK) signalling pathway in 1C-treated cancer cells was also observed. On the other hand, co-treatment of cells with strong antioxidant, N-acetyl cysteine (NAC), significantly attenuated all of the above-mentioned effects of chalcone 1C, that is, decreased oxidant production, prevent mitochondrial dysfunction, DNA damage, and induction of apoptosis, as well as partially preventing the activation of MAPK signalling. Taken together, we documented the role of ROS in the antiproliferative/pro-apoptotic effects of acridine chalcone 1C. Moreover, these data suggest that this chalcone may be useful as a promising anti-cancer agent for treating colon cancer.Entities:
Keywords: antiproliferative; chalcones; oxidative stress
Year: 2020 PMID: 32098428 PMCID: PMC7072140 DOI: 10.3390/biom10020345
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Flow cytometry staining.
| Analysis | Staining Solution | Manufacturer |
|---|---|---|
| ROS | DHR123 (Dihydrorhodamine 123), final concentration 200 nM | Sigma-Aldrich, St. Louis, MO, USA |
| RNS | DAF-FM (Diaminofluorescein-FM) diacetate, final concentration 2 mM | Sigma-Aldrich, St. Louis, MO, USA |
| Lipid peroxidation | BODIPY 581/591 C11, final concentration 1 mM | Sigma-Aldrich, St. Louis, MO, USA |
| Superoxide anion | MitoSox Red mitochondrial superoxide indicator, final concentration 5 µM | Sigma-Aldrich, St. Louis, MO, USA |
| Externalization of phosphatidylserine | Annexin V-FITC, 1:100 | BD Biosciences Pharmingen, San Diego, CA, USA |
| Caspase-3 activation | Cleaved caspase-3-PE, 1:200 | BD Biosciences Pharmingen, San Diego, CA, USA |
| Cytochrome | Cytochrome | Invitrogen, Carlsbad, CA, USA |
| Smac/DIABLO release | Smac/DIABLO rabbit mAb, 1:200 | Cell Signaling Technology, Danvers, MA, USA |
| Goat anti-rabbit IgG (H + L) secondary antibody, Alexa Fluor 488, 1:500 | Thermo Scientific, Rockford, IL, USA | |
| Mitochondrial membrane potential | TMRE (tetramethylrhodamine ethyl ester perchlorate), final concentration 0.1 µM | Sigma-Aldrich, St. Louis, MO, USA |
| Protein analysis | Phospho-Bcl-2 (Ser70) rabbit mAb Alexa Fluor 488 conjugate, 1:200 | Cell Signaling Technology, Danvers, MA, USA |
| Goat anti-rabbit IgG (H+L) secondary antibody, Alexa Fluor 488, 1:500 | Thermo Scientific, Rockford, IL, USA | |
| DNA damage | Anti-pATM, PE conjugated antibody, 1:200 | Millipore Corporation, Temecula, CA, USA |
| Anti-oxoguanine 8 antibody | Abcam, Cambridge, United Kingdom | |
| Goat anti-mouse IgG (H + L) secondary antibody, Alexa Fluor 488 | Thermo Scientific, Rockford, IL, USA |
List of Western blot antibodies.
|
|
|
|
|
| β-actin | 45 | Mouse | Cell Signaling Technology, Danvers, MA, USA |
| p38 MAPK | 43 | Rabbit | |
| Phospho-p38MAPK | 43 | Rabbit | |
| p44/42 MAPK (Erk1/2) | 42 + 44 | Rabbit | |
| Phospho-p44/42 MAPK (Erk 1/2) | 42 + 44 | Mouse | |
| JNK1 | 48 | Mouse | |
| Phospho-SAPK/JNK | 54 | Mouse | |
| Cleaved caspase-7 | 18 | Rabbit | |
| PARP | 116 + 89 | Rabbit | |
| Phospho-histone H2A.X | 15 | Rabbit | |
|
|
|
|
|
| Anti-rabbit IgG HRP | - | Goat | Cell Signalling Technology, Danvers, Massachusetts, USA |
| Anti-mouse IgG/HRP | - | Goat | Dako, Glostrup, Denmark |
JNK1- c-Jun N-terminal kinase; SAPK- Stress-activated protein kinase; PARP- Poly (ADP-ribose) polymerase.
Figure 1HCT116 cell proliferation treated with chalcone 1C ((2 E)-3-(acridin-9-yl)-1-(2,6-dimethoxyphenyl)prop-2-en-1-one) alone (A) or in combination (N-acetyl cysteine (NAC)/1C) (B) and after NAC dilutions (C). Data were obtained from three independent measurements. Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 2The influence of 1C and NAC/1C on free radical production in HCT116 cells. (A) Measurement of reactive oxygen species (ROS) levels after 6, 24, 48, and 72 h incubation (B) Relative levels of reactive nitrogen species (RNS) after 6, 24, 48, and 72 h incubation (C) Relative levels of superoxide after 3, 6, 24, 48, and 72 h incubation (D) Analysis of lipoperoxide production after 6, 24, 48, and 72 h incubation. Data were obtained from three independent measurements. Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 3Oxidative DNA damage detection using 8-oxo-7,8-dihydroguanine (8-oxoG) level measurement after 24, 48, and 72 h incubation of HCT116 cells with 1C and NAC/1C. Significantly different c p < 0.001 vs. untreated cells (control); ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 4Antioxidant status of HCT116 cells after 1C, NAC, and NAC/1C treatment. The influence of 1C and combination of NAC/1C on glutathione content (A), glutathione peroxidase (GPx) activity (B), glutathione reductase (GR) activity (C), and glutathione-S-transferase (GST) activity (D). The experiments were performed in triplicate and measured parameters were calculated per milligram or kilogram of protein vs. untreated cells (control).
Figure 5Representative histograms of cell cycle distribution in HCT116 cells treated with NAC, 1C, or NAC/1C after 24, 48, and 72 h.
Cell cycle analysis of HCT116 cells after 24, 48 and 72 h incubation with NAC, 1C, or NAC/1C.
| SubG0/G1 | G1 | S | G2 | |
|---|---|---|---|---|
|
| 1.77 ± 0.74 | 44.65 ± 0.65 | 28.45 ± 2.55 | 25.25 ± 2.55 |
|
| 2.71 ± 1.36 | 41.30 ± 2.80 | 25.55 ± 0.45 | 30.60 ± 3.50 |
|
| 11.30 ± 2.31 b | 29.25 ± 3.15 b | 14.40 ± 2.10 b | 45.25 ± 1.45 c |
|
| 4.25 ± 1.23 a** | 50.75 ± 3.45 *** | 15.85 ± 4.45 b | 29.35 ± 2.35 ** |
|
| 0.95 ± 0.65 | 55.45 ± 6.45 | 19.10 ± 6.50 | 24.30 ± 0.90 |
|
| 1.92 ± 0.38 | 47.95 ± 0.15 | 23.60 ± 2.00 | 26.55 ± 2.55 |
|
| 11.85 ± 0.55 b | 31.80 ± 2.20 b | 17.75 ± 2.65 | 38.35 ± 1.25 b |
|
| 5.55 ± 0.95 a*** | 52.95 ± 0.35 ** | 16.85 ± 3.85 | 24.50 ± 3.20 ** |
|
| 0.71 ± 0.03 | 68.30 ± 6.00 | 13.25 ± 1.95 | 17.85 ± 4.45 |
|
| 1.53 ± 0.77 | 68.95 ± 6.35 | 14.75 ± 2.55 | 14.55 ± 3.15 |
|
| 15.63 ± 7.18 b | 26.25 ± 1.95 c | 18.80 ± 1.00 | 39.00 ± 4.20 b |
|
| 3.85 ± 1.24 a* | 67.75 ± 0.65 *** | 10.65 ± 1.65 ** | 17.75 ± 0.25 ** |
The results are presented from three independent measurements as the mean ± standard deviation (SD). Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 6Representative dot-blot diagrams of annexin V/PI staining in HCT116 cells after treatment with NAC, 1C, and NAC/1C.
Externalization of phosphatidylserine after treatment with NAC, 1C, and NAC/1C.
| Live (Q1) | Early Apoptotic (Q2) | Late Apoptotic (Q3) | Death (Q4) | |
|---|---|---|---|---|
|
| 97.80 ± 0.65 | 0.05 ± 0.04 | 0.18 ± 0.10 | 2.00 ± 0.49 |
|
| 90.95 ± 1.67 | 1.61 ± 1.14 b | 6.20 ± 3.43 b | 1.23 ± 0.633 b |
|
| 68.50 ± 0.98 c | 17.84 ± 2.25 c | 3.99 ± 0.99 c | 9.78 ± 0.34 c |
|
| 86.65 ± 1.59 b*** | 10.92 ± 2.35 c*** | 0.71 ± 0.32 b** | 1.75 ± 0.45 *** |
|
| 93.55 ± 0.86 | 1.37 ± 0.53 | 2.28 ± 0.62 | 2.75 ± 2.00 |
|
| 91.50 ± 0.98 | 0.16 ± 0.13 | 8.10 ± 0.65 b | 0.27 ± 0.19 b |
|
| 42.55 ± 5.76 c | 16.53 ± 2.96 c | 17.23 ± 5.69 c | 23.70 ± 3.02 c |
|
| 62.15 ± 1.84 b** | 10.49 ± 0.35 c* | 15.61 ± 3.66 c | 11.75 ± 1.43 b** |
|
| 94.30 ± 0.41 | 0.78 ± 0.21 | 1.38 ± 0.51 | 3.56 ± 0.29 |
|
| 94.95 ± 0.20 | 0.06 ± 0.05 c | 4.85 ± 0.05 | 0.17 ± 0.09 |
|
| 31.85 ± 5.59 c | 11.29 ± 0.58 c | 25.71 ± 4.07 c | 31.20 ± 0.89 c |
|
| 61.10 ± 1.23 b** | 8.83 ± 1.48 c* | 11.83 ± 0.96 b* | 18.24 ± 0.70 b*** |
The results are presented from three independent measurements as the mean ± standard deviation (SD). Significantly different b p < 0.01, c p < 0.001 vs. untreated cells (control); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 7Mitochondrial apoptotic pathway alteration in 1C-treated and NAC/1C-co-treated HCT116 cells represented by cytochrome c release (A), expression of Smac/DIABLO (B), and caspase-3 (C) or caspase-7 activation and PARP cleavage (D). Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 8Mitochondrial membrane potential changes after 1C or NAC/1C treatment. Significantly different b p < 0.01, c p < 0.001 vs. untreated cells (control); ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 9Relative levels of phosphorylated bcl-2 after 24, 48, and 72 h of 1C or NAC/1C treatment. Significantly different b p < 0.01 vs. untreated cells (control); *** p < 0.001 vs. 1C.
Figure 10Analysis of DNA damage-related proteins. Phospho histone H2A.X (A,D), phospho-ataxia telangiectasia mutated kinase (ATM), (B) and phospho-structural maintenance of chromosomes 1 (SMC1) (C) levels after 24, 48, and 72 h of 1C or NAC/1C treatment. Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); * p < 0.05, ** p < 0.01, *** p < 0.001 vs. 1C.
Figure 11Phosphorylation status of mitogen-activated protein kinase (MAPK) proteins. Phosphorylation changes of p38 MAPK (A,D), JNK (B,D), and ERK1/2 (C,D) as the result of 1C or NAC/1C combination treatment. Significantly different a p < 0.05, b p < 0.01, c p < 0.001 vs. untreated cells (control); ** p < 0.01, *** p < 0.001 vs. 1C.